Sherlock discovers novel CRISPR-associated enzymes

By The Science Advisory Board staff writers

December 7, 2020 -- Sherlock Biosciences has announced the discovery of novel thermostable CRISPR-associated (Cas) enzymes.

The thermostable proteins enable real-time detection of RNA and DNA targets. They also advance multiplexing abilities to detect multiple targets in a single test with Sherlock's licensed Cas12 and Cas13 enzymes.

Sherlock discovered the Cas enzymes in partnership with researchers from Rosetta Biosciences. Rosetta utilized its artificial intelligence engine and protein design platform to create a pipeline of novel Cas enzymes.

If you like this content, please share it with a colleague!

Related Reading

Sherlock launches nonprofit to promote equity, STEM during COVID-19
Sherlock Biosciences has formed the 221b Foundation, a nonprofit organization committed to assisting in the eradication of COVID-19, while supporting...

Sherlock, Binx to develop rapid CRISPR COVID-19 test
Sherlock Biosciences and Binx Health have partnered to create a rapid, point-of-care test for COVID-19 utilizing CRISPR technology.

CRISPR proteins developed for use in molecular diagnostics
New CRISPR technology is being developed as a molecular diagnostic tool with the capability of detecting unique disease biomarkers. Eventually, these...

New CRISPR Cas13 system offers powerful antiviral protection
A first-of-its-kind study conducted by researchers at the Broad Institute of MIT and Harvard demonstrates that Cas13, a class 2 CRISPR system, can be...